Research and Clinical Trials

Role: Principal Investigator

A Randomized, Double-Blind, Placebo-Controlled, Efficacy Study Of The Neurokinin-L Receptor Antagonist VLY-686 In Patients With Atopic Dermatitis (VP- VLY-686-3102)

Sponsor: Vanda Pharmaceutics Inc.

October 2019--Ongoing


A Randomized, Double-Blind, Placebo-Controlled, Efficacy Study Of The Neurokinin-1 Receptor Antagonist Vly-686 In Patients With Atopic Dermatitis (VP-VLY-686-3101)

Sponsor: Vanda Pharmaceuticals Inc.

June 2018-December 2019


A Multicenter, Open-Label Study To Assess The Long-Term Safety, Tolerability, And Efficacy Of Bimekizumab In Adult Subjects With Moderate To Severe Chronic Plaque Psoriasis

Sponsor: UCB Biopharma SPRL

September 2018--0ngoing


A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study With An Initial Treatment Period Followed By A Randomized Withdrawal Period To Evaluate The Efficacy And Safety Of Bimekizumab In Adult Subjects With Moderate To Severe Chronic Plaque Psoriasis

Sponsor: UCB Biopharma SPRL

February 2018-January 2020


A Phase 2b Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose Ranging Study To Evaluate The Efficacy And Safety Proflle Of Pf-06651600 With A Partially Blinded Extension Period To Evaluate The Efficacy And Safety Of Pf- 06651600 And Pf-06700841 In Subjects With Active Non-Segmental Vitiligo

Sponsor: Pfizer

November 2018--Ongoing


A Phase 3 Open-Label, Multi-Center, Long-Term Study Investigating The Safety And Efficacy Of Pf-06651600 In Adult And Adolescent Participants With Alopecia Areata

Sponsor: Pfizer

July 2019--0ngoing


A Phase 2B/3 Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Studyto Investigate the Efficacy and Safety of PF-06651600 in Adult and Adolescent Alopecia Areata (AA) Subjects with 50% or Greater Scalp Hair Loss

Sponsor: Pfizer

December 2018--0ngoing


A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study To Demonstrate The Efficacy, Safety And Tolerability Of Subcutaneous Secukinumab Injections With 2 Ml Auto-Injectors (300 Mg) In Adult Subjects With Moderate To Severe Plaque Psoriasis - MATURE

Sponsor: Novartis

September 2019--Ongoing


A Randomized, Double-Blind, Multicenter Study Assessing Short (16 Weeks) And Long-Term Efficacy (Up To 1 Year), Safety, And Tolerability Of Sub- Cutaneous Secukinumab In Subjects Of Body Weight 90 Kg Or Higher With Moderate To Severe Chronic Plaque-Type Psoriasis

Sponsor: Novartis

June 2018--0ngoing


An Open-Label Long-Term Safety Study Of Serlopitant For The Treatment Of Pruritus

Sponsor: Menlo Therapeutics Inc.

March 2018--0ngoing


A Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy, Safety, And Tolerability Of Serlopitant For The Treatment Of Pruritus In Adults With Prurigo Nodularis

Sponsor: Menlo Therapeutics Inc.

May 2018-0ngoing


A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of Gbr 830 In Adult Subjects With Moderate To Severe Atopic Dermatitis

Sponsor: Glenmark Pharmaceuticals SA

May 2018--0ngoing


A Long-Term, Open-Label, Extension Study to Evaluate the Safety and Efficacy of Tapinarof Cream, 1% for the Treatment of Plaque Psoriasis in Adults

Sponsor: Dermavant Sciences GmbH

November 2019-0ngoing


A Phase 3 Efficacy and Safety Study of Tapinarof for the Treatment of Plaque Psoriasis in Adults

Sponsor: Dermavant Sciences GmbH

June 2019-February 2020


A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan in Subjects with Moderate to Severe Hidradenitis Suppurativa

Sponsor: ChemoCentryx, Inc

December 2018-0ngoing


A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose Ranging Study Investigating the Efficacy, Safety, and Pharmacokinetic Profile of ANB020 Administered to Adult Subjects with Moderate-to-Severe Atopic Dermatitis

Sponsor: AnaptysBio, Inc.

May 2018-January 2020


A Phase 3 Open Label Safety Study Of A-101 Topical Solution For The Treatment Of Common Warts

Sponsor: Aclaris Therapeutics, Inc.

February 2019-January 2020


A Phase 3 Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study Of A-101 Topical Solution Applied Twice A Week In Subjects With Common Warts

Sponsor: Aclaris Therapeutics, Inc.

July 2017-April 2019


A Multicenter, Open Label Study To Assess The Safety And Efficacy Of Risankizumab For Maintenance In Moderate To Severe Plaque Type Psoriasis (LIMITLESS)

Sponsor: AbbVie

February 2017-0ngoing


A 52 week, Multi-center, Randomized, Double-blind Study of Secukinumab (300mg) to Demonstrate efficacy as Assesses by Psoriasis Area and Severity Index an Investigator's Global Assessment after 12 weeks of Treatment, Compared to Ustekinumab, and to Assess Long-term Safety, tolerability and Efficacy in Subjects with Moderate-to-Severe plaque psoriasis.

Sponsor: Novartis Pharmaceuticals, Inc

October 2016 -July 2018


A Multi-center, Randomized, Double-Blind, Placebo-Controlled, 52 Week Study to Demonstrate the Efficacy, Safety and Tolerability of Subcutaneous Secukinumab injections with 2ml Pre-filled Syringes (300mg) in Adult Subjects with Moderate-to Severe Plaque Psoriasis

Sponsor: Novartis Pharmaceuticals, Inc

February 2017- November 2019


A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center study to explore changes in Subcutaneous Adipose tissue and Modulation of skin Inflammation after 12 weeks of Treatment with Secukinumab,compared to placebo, and up to 52 weeks of treatment with Secukinumab in Adult Patients with Moderate -to-Severe plaque psoriasis (ObePso- S)

Sponsor: Novartis Pharmaceuticals, Inc

April 2017-February 2019


A Multi-center, Randomized, Double-blind, Parallel-Group, vehicle-controlled study to evaluate the dose response relationship of the efficacy and safety of two concentrations of DFD-07 (celecoxib) cream in subjects with actinic keratosis.

Sponsor: Dr. Reddy

January 2017-March 2018


A Multi-centre, Double-blind, randomized, vehicle-controlled study of efficacy and safety of topical MOB015B in the treatment of mild to moderate distal subungual.

Sponsor: Moberg

August 2016-August 2017


A Phase 2B Randmized, Double-blind, Placebo-Controlled, Parallel, Multi-center, Dose-ranging, Study to Evaluate The Efficacy and Safety Proftle of PF-04965842 In Subjects With Moderate-to-Severe Atopic Dermatitis

Sponsor: Pfizer

May 2016 -June 2017


A Phase 3, Randomized, Vehicle-Controlled, Double-blind, Mulitcenter Study to Evaluate the Safety and Efficacy of a Once Daily CLS00l Topical Gel Versus Administered for 12 Weeks to Subjects with Papulopustular Rosacea with a 4 Week Follow-up Period

Sponsor: Cutanea Life Sciences, Inc.

January 2016 -- November 2016


Efficacy and Safety of Leo 43204 in Field Treatment of Actinic Keratosis on Balding Scalp including 12 follow-up

Sponsor: Leo Pharmaceuticals

December 2015 - January 2018


An Open-Label Study of Dupilumab in Patients with Atopis Dermatitis Who Participated in Previous Dupilumab Clinical Trials.

Sponsor: Regeneron

October 2015 - May 2017


A Phase 3, Randomized, Double-blind, Placebo-Controlled Study Investigating the Efficacy and Safety of Multiple Dupilumab Dose Regimens Administered as Monotherapy for Mainting Treatment Response in Patients with Atopic Dermatitis

Sponsor: Regeneron

August 2015 - November 2016


A Multicenter, Randomized, Double-blind, Placebo-Controlled and active controlled Phase 2 Dose-finding study of QGE031 as add-on therapy to investigate the efficacy and safety in patients with Chronis Sponraneous Urticaria

Sponsor: Novartis Pharmaceuticals, Inc.

August 2015 - May 2016


A Phase 3 Confirmatory Study Investigating The Efficacy And Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate to Severe Atopic Dermatitis

Sponsor: Regeneron

March 2015 -May 2016


A Phase 2 , Multi-center Study to Evaluate the Safety, Pharmacokinectics, and Preliminary Efficacy of Asimadoline in Adult Subjects with Pruritis Associated with Atopic Dermatitis

Sponsor: Tioga Pharmaceuticals

March 2015 - July 2017


Efficacy and Safety of lngenol Mebutate Gel in Field Treatment of Actinic Keratosis on Full Face, Balding Scalp or Approximately 250 cm2 on the Chest

Sponsor: Leo Pharmaceuticals

March 2015 - January 2018


An Open-Label Study of Dupilumab in Patients with Atopic Dermatitis Who Participated in Previous Dupilumab Clinical Trials

Sponsor: Regeneron

October 2015 - May 2017


A Single-arm Study to Assess the Immunogenicity and Safety of Eternacept Produced Using a Modified Process in Subjects With Plaque Psoriasis

Sponsor: Amgen

January 2015-- July 2015


A Phase 2b, Randomized, Double-blind, Placebo Controlled, Phase II Study to Assess The Efficacy And Safety of Orally Administered DS107G to Patients With Moderate to Severe Atopic Dermatitis

Sponsor: Dignity Sciences

January 2015 -May 2016


A Phase 2b, Randomized, Double-blind, Placebo-Controlled, Dose ranging Study to Evaluate the Efficacy and Safety of Tralokinumab in Adult Subjects with Moderate to- Severe Atopic Dermatitis.

Sponsor: Medimmune

January 2015-- May 2016


A Randomized, Multi-center, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of 1.5 ,g/kg Day of Sarecycline Compared to Placebo in the Treatment of Acne Vulgaris

Sponsor: Allergan

October 2014- August 2016


An Open-Label Study ofDupilumab in Patients with Atopic Dermatitis WhoParticipated in Previous Dupilumab Clinical Trials

Sponsor: Regeneron

October 2015 - May 2017


A Phase 3 Confirmatory Study Investigating The Efficacy And Safety Of Dupilumab Monotherapy Administered in Adult Patients with Moderate-to-Severe Atopic Dermatitis

Sponsor: Regeneron

April 2015 - April 2016


A Randomized, Double-blind, Placebo-Controlled Study To Demonstrate The Efficacy And Long-Term Safey of Dupilumab in Adult Patients with Moderate-to Severe Atopic Dermatitis

Sponsor: Regeneron

September 2014-- November 2016


A Phase 3, Randomized, Double-blind, Placebo-Controlled Study Investigating the Efficacy and Safety of Multiple Dupilumab Dose Regimens Administered as Monotherapy for Maintaining Treatment Response in Patients with Atopic Dermatitis

Sponsor: Regeneron

September 2015-- February 2017


A Phase 2 Randomized, Double-blind, Multi-center, Parallel- Group, Placebo Controlled Study to Assess the Efficacy and Safety of Three Dose Levels of XP23829 in Subjects with Chronic Plaque-Type Psoriasis

Sponsor: XenoPort Inc.

June 2014-October 2015


A Phase 2 Multi-center, Randomized, Double-blind, Vehicle-Controlled, Three-arm, Parallel Group Study to Assess the Safety, Tolerability , and Efficacy of Topical OPA-15406 Ointment, in Subjects With Mild/Moderate Atopic Dermatitis

Sponsor: Otsuka Pharmaceuticals

June 2014-April 2015


An Open Label Extension Trial Assessing the Safety and Efficacy of BI 655066 Administered subcutaneously in Patients with Moderate-to-Severe Chronic Plaque Psoriasis

Sponsor: Boehringer Ingelheim

April 2014 - Ongoing


A 48 Weeks Study of Three different Dose Regimens of BI655066 Administered Subcutaneously in Patients With Moderate-to-Severe Chronic Plaque Psoriasis - Randomized, Dose- ranging, Active-comparator controlled (Ustekinumab), Double blind Within Dose Groups of BI

Sponsor: Boeringer Ingelheim

December 2013 - October 2015


A Safety And Efficacy Study To Compare Dapsone Dermal Gel with Vehicle Controlled in Patients with Acne Vulgaris

Sponsor: Allergan

November 2013 -December 2014


A Phase 2, Randomized, Double-blind, Vehicle Control, Dose-Randing Study of the Effect of DRM04B in Subjects with Axillary Hyperhidrosis

Sponsor: Dermira, Inc

November 2013 -October 2014


Safety and Efficacy of Escalating Doses of Two LEO 43204 Formulations applied Once Daily for Two Consecutive Days On Full Face or Approximately 250cm2 (40in2 on the Chest in Subjects with Actinic Keratosis

Sponsor: LEO Pharma A/S

October 2013 - May 2015


An Open-Label, Proof of Concept Study of Gevokizumab in The Treatment of The Acne, Inflammatory Phase of Pyoderma Gangrenosum

Sponsor: XOMA (US) LLC

September 2013 -April 2014


A Phase II, Randomized, Double-Blind, Parellel-Group, Placebo-Controlled, Dose Finding, and Efficacy Study ofVPD-737 in the Treatment of Subjects with Chronic Pruritis

Sponsor: Tigercat Pharma

August 2013-April 2015


A Phase 3 Trial Comparing Once Daily Treatment with LEO 90100 Calcipotriol 50mcg/g plus Betamethasone 0.5mg/g (As Dipropionate) with Vehicle in Subjects with Psoriasis Vulgaris.

Sponsor: LEO Pharmaceuticals

August 2013-April 2015


A Multi-center, Prospective, Randomized, Double-blinded, 2 arm, parallel group, 4- Week Trial in Subjects with Psoriasis Vulgaris

Sponsor: Leo Pharmaceuticals

August 2013-December 2013


Post Approval Study of Melafind®

Sponsor: MELA Sciences, Inc

July 2013-May 2016


Qualitative Assessment of MelaFind® in the Clinical Setting

Sponsor: MELA Sciences, Inc

January 2012-February 2012


A Multi-center, Randomized, Double-blind, Placebo-Controlled Study Comparing the Efficacy and Safety ofLY2439821 to Etanercept and Placebo in Patients with Moderate-to-Severe Plaque Psoriasis

Sponsor: Eli Lilly

August 2013 - January 2014


A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens ofBrodalumac Compared With Placebo and Ustekinumab in Subjects With Moderate-to-Severe Plaque Psoriasis: AMAGINE 3

Sponsor: AMGEN Incl

October 2012 -March 2017


A Multi-center, Randomized, Placebo-Controlled, Double- Blind Parallel-group Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ASB17061 Capsulesin Adult Subjects With Atopic Dermatitis

Sponsor: Asubio Pharmaceuticals

December 2012 -April 2014


A Multi-center, Double-Blind and Open Label, 4 Year Extension Study Of Subcutaneous Secukinumab in Prefilled Syinges, Assessing Long-Term Safety, tolerability and Efficacy in Subjects with Moderate-to-Severe Chronic Plaque-Type Psoriasis Treated with either a Fixed Dose Regimen or on Retreatment at Start of Relaspe regimen

Sponsor: Novartis Pharmaceuticals, Inc

July 2012 -August 2017


A Phase II Randomized, Double-blind, Placebo-Controlled, Multiple-Dose Regimen Study to Assess the rate of Histological Clearance and effect on Molecular Pathways as Well as Biomarkers on 12 Months Secukinumab 300mg s.c. treated Patients with Chronic Plaque-type Psoriasis

Sponsor: Novartis Pharmaceuticals, Inc

September 2012 - April 2015


A Randomized, Double-Blind, Multi-center study of Subcutaneous Secukinumab, Assessing Psoriasis Area and Severity Index (PASI) response and Maintenance pf response in Subjects with Moderate-to-Severe Chronic Plaque-type psoriasis on either a fixed Dose regimen or on a Retreatment at Start of Relapse regimen

Sponsor: Novartis Pharmaceuticals, Inc

August 2011-- August 2013


A Randomized, Double-Blind, Vehicle-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of AN2690 Topical Solution, 5% vs. Solution Vehicle in the Treatment of Onychomycosis of the Toenail in Adults

Sponsor: Anacor Pharmaceuticals

January 2011 -August 2012


An Open Label Study to Evaluate the Effiacy of Eternacept Treatment in Subjectswith Moderate-to-Severe Patients Who Have Lost Satisfactory Response to Adalimumab

Sponsor: AMGEN Inc

July 2012 -August 2015


A Phase 3 Open-Label Study of the Safety and Efficacy of Adalimumab in Subjectswith Moderate-to-Severe Hidradenitis Suppuritiva

Sponsor: Abbvie

March 2012-May 2013


A Phase 3 Multi-center Study of the Efficacy and Safety of Adalimumab in Subjects with Moderate-to-Severe Hidradenitis Suppuritva

Sponsor: Abbvie

October 2011 -October 2014


Calcipotriol Plus Betamethasone Dipropionate Topical Suspension Compared to Betamethasone Dipropionate in the Topical Suspension Vehicle, Calcipotriol in the Topical Suspension Vehicle and the Topical Suspension Vehicle Alone in Psoriasis Vulgaris

Sponsor: Leo Pharmaceuticals

September 2010- September 2012


A Multicenter, Open Registry of Patients with Psoriasis Who Are Candidates for Systemic Therapy Including Biologics

Sponsor: Centocor, Ortho Biotech, Inc.

June 2010 - Ongoing


A Phase III, Mulitcenter, Randomized, Double-Blind Study Evaluating the Safety and Efficacy ofIDP-108 Topical Solution vs. Vehicle in Subjects with Mild to Moderate Onychomycosis of the Toenails

Sponsor: Dow Pharmaceutical Sciences, Inc.

November 2009 - September 2011


A 10-Year Post-Marketing, Observational, Registry ofHUMIRA® (Adalimumab) inAdult Patients with Chronic Plaque Psoriasis

Sponsor: Abbott Laboratories

November 2009-Ongoing


Pre-Commercial Qualitative Assessment of MelaFind® in the Clinical Setting

Sponsor: MELA Sciences, Inc.

September 2010-December 2010.


A Phase II, Multicenter, Randomized, Double-Blind, Parallel-Group, Comparative Study of FV-100 vs. Valacyclovir in Patients with Herpes Zoster

Sponsor: Inhibitex, Inc.

October 2009 - October 2010.


A Prospective, Multicenter, Parallel, Randomized, Blinded Study of the Efficacy and Safety of the DTS G2 System in Patients with Axillary Hyperhidrosis (Pivitol)

Sponsor: Miramar Labs, Inc.

June 2009-February 2011.


Clinical Evaluation of the DTS-G2 in Patients with Hyperhidrosis (Feasibility)

Sponsor: Miramar Labs, Inc.

February 2009 - June 2010.


A Phase 3 Open-Label Study of the safety and efficacy of Adalimumab in Subjects with Moderate to Severe Hidradenitis Suppurativa.

Sponsor: Abbvie

May 2007-- May 2013



*All listed investigations are in accordance with the Investigational Plan provided by the Study Sponsor, signed agreements, 21 CFR 812.2 (b),Abbreviated Requirements, the Declaration of Helsinki, and any conditions of approval imposed by reviewing IRB/EC or the U.S. Food and Drug Administration (FDA). Informed consent is obtained per applicable requirements.

Mount Sinai School of Medicine, Department of Dermatology Mentor: James Spencer

  • Treatment of vitiligo with UV-308 laser phototherapy. August 1999 - March 2000. The purpose of this study was to evaluate the efficacy ofUV-308 laser phototherapy for the treatment ofvitiligo. Acquired and treated patients; created data sheets; analyzed data; reviewed literature; prepared manuscripts for publication.

New York University, Oncology Section, Skin and Cancer Unit.

  • Large congenital melanocytic nevus follow-up study. June- September 1994. Reviewed historical literature on malignant melanoma evolving in largecongenital melanocytic nevi, to supplement NYU Melanoma Cooperative Group data base analysis. The study demonstrated that, based on a cumulativefive year life-table analysis, our study population, with large congenital melanocytic nevi, had significantly increased risk for developing malignant melanoma.

New York University, Oncology Section, Skin and Cancer Unit.

  • Neoangiogenesis as a prognostic indicator in melanoma. September 1992-July 1993. Created a study protocol, database, and data sheets to be used by histopathologists reviewing the cases. Reviewed the NYU Melanoma Cooperative Group data base for adequate case specimens. Responsible for collecting pertinent step sectioned histologic slides and verifying proper staining with Factor VII, CD-31, and CD-34 immunoperoxidase stains.